Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Therion's course for HIV vaccine

Therion's course for HIV vaccine

By Karen Bernstein Editor-in-ChiefTherion Biologics Corp. has taken up the challenge of developing a live, attenuated HIV vaccine, although the research is more likely to result in other products than it is in the commercialization of a live vaccine.

Therion

Read the full 471 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE